文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

GLP-1受体激动剂与SGLT2抑制剂及自身免疫性风湿病风险

Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.
PubMed 文献 · Arthritis Rheumatol · 2026-02-24

在加拿大某省医疗数据库中,纳入229300例无既往自身免疫性风湿病的2型糖尿病成人,比较启动GLP-1RA、SGLT2i与DPP4i后自身免疫性风湿病发病率。经倾向评分加权,GLP-1RA和SGLT2i相比DPP4i均未显著改变总体自身免疫性风湿病风险,但SGLT2i与系统性自身免疫性风湿病风险降低相关(aHR 0.51,95%CI 0.31-0.84)。

要点

  • 2型糖尿病成人中,GLP-1RA与SGLT2i均未增加或降低总体自身免疫性风湿病风险。
  • SGLT2i相比DPP4i与系统性自身免疫性风湿病风险降低相关。
  • GLP-1RA相比DPP4i的自身免疫性风湿病风险无显著差异。

核心结论

  • 在2型糖尿病成人中,GLP-1RA或SGLT2i治疗相比DPP4i未与自身免疫性风湿病风险升高或降低相关。
  • SGLT2i使用与系统性自身免疫性风湿病风险显著降低相关,需进一步研究。

研究设计与样本

  • 基于加拿大某省全民医疗行政健康数据的人群队列研究。
  • 共229300例,其中49514例启动GLP-1RA、101925例启动SGLT2i、77861例启动DPP4i。
  • 采用倾向评分加权平衡组间基线,Cox回归估计风险比。

主要发现

  • 倾向评分加权后,每万人年自身免疫性风湿病发病率:GLP-1RA为29.1(95%CI 23.5-35.5),SGLT2i为24.4(95%CI 19.8-29.7),DPP4i为27.3(95%CI 22.1-33.4)。
  • 平均随访1.3至1.6年。
  • 相比DPP4i,GLP-1RA的自身免疫性风湿病校正风险比为1.04(95%CI 0.81-1.33)。
  • 相比DPP4i,SGLT2i的自身免疫性风湿病校正风险比为0.93(95%CI 0.75-1.16)。
  • SGLT2i相比DPP4i与系统性自身免疫性风湿病风险降低相关,校正风险比0.51(95%CI 0.31-0.84)。

关键数值与推荐

  • 自身免疫性风湿病包括类风湿关节炎、银屑病性疾病、中轴型脊柱关节炎及系统性自身免疫性风湿病,采用经验证算法识别。
  • 系统性自身免疫性风湿病包括系统性红斑狼疮、系统性硬化症、干燥病、特发性炎性肌病和系统性血管炎。

临床怎么用

  • 在2型糖尿病合并自身免疫性风湿病风险人群中,GLP-1RA和SGLT2i未显示总体自身免疫性风湿病风险增加。
  • SGLT2i与系统性自身免疫性风湿病风险降低的关联可作为进一步研究的信号,尚不足以据此改变临床决策。

局限性

  • 平均随访时间较短(1.3至1.6年)。
  • 观察性设计可能残留混杂。
  • 系统性自身免疫性风湿病事件数较少,相关估计需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP-1RAs or SGLT2i versus a weight-neutral comparator (dipeptidyl peptidase 4 inhibitors [DPP4i]). METHODS: We performed a population-based cohort study using administrative health data from a Canadian province with universal health care. We included adults with type 2 diabetes (T2D) and no prior ARD initiating a GLP-1RA, SGLT2i, or DPP4i between January 1, 2014, and December 31, 2022. Incident ARD cases, including rheumatoid arthritis, psoriatic disease, axial spondyloarthritis, and systemic ARDs (SARDs; systemic lupus erythematosus, systemic sclerosis, Sjögren disease, idiopathic inflammatory myopathies, and systemic vasculitides), were identified using validated algorithms. Propensity score (PS) weighting was used to balance cohorts at treatment initiation. Then hazard ratios (HRs) were estimated using Cox regression. RESULTS: Among 229,300 adults, 49,514 initiated GLP-1RAs, 101,925 initiated SGLT2i, and 77,861 initiated DPP4i. After PS weighting, ARD incidence per 10,000 person-years was 29.1 (95% confidence interval [CI] 23.5-35.5) with GLP-1RAs, 24.4 (95% CI 19.8-29.7) with SGLT2i, and 27.3 (95% CI 22.1-33.4) with DPP4i. Mean follow-up was 1.3 to 1.6 years. Relative to DPP4i, adjusted HRs (aHRs) of ARD were 1.04 (95% CI 0.81-1.33) with GLP-1RAs and 0.93 (95% CI 0.75-1.16) with SGLT2i. Risk of SARDs, but not other diseases, was lower with SGLT2i versus DPP4i (aHR 0.51 [95% CI 0.31-0.84]). CONCLUSION: Neither GLP-1RA nor SGLT2i treatment was associated with increased or decreased ARD risk versus DPP4i in adults with T2D; however, SGLT2i use was associated with significantly lower risk of SARDs, warranting further study.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Karacabeyli D, Lacaille D, Lu N, et al. Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2026. PMID: 41466578. doi:10.1002/art.70044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。